Received Jun 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 2 | Y020531 | — |
No additional adverse event was reported; A HCP transferred from a MVCC CRT agent called to inquire about GARDASIL 9 and whether or not the series should be restarted for a 45-year-old patient who received an initial dose sometime in 2021 and a second dose yesterday, 06/08/2025. The HCP stat; This spontaneous report was received from a pharmacist and refers to a 45-year-old female patient. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On 2021, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), dose number 1, (indication, expiration date, and lot # were not reported). On 08-Jun-2025, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot #Y020531, expiration date: 05-Aug-2027), dose number 2, 0.5 mL for an unknown indication (Inappropriate schedule of vaccine administered). No additional adverse event was reported.